Yuzhen Liu

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Fred Saad, Noel W. Clarke, Mototsugu Oya et al. · The Lancet Oncology · 2023 · 288 citations · Full text

Medicine, Oncology, Pharmacology +16

A role for FAK in the Concanavalin A-dependent secretion of matrix metalloproteinase-2 and -9

Thet Thet Sein, Aye Aye Thant, Yukiko Hiraiwa et al. · Oncogene · 2000 · 80 citations

Life Sciences, Biochemistry, Molecular Biology +9

High throughput data-based, toxicity pathway-oriented development of a quantitative adverse outcome pathway network linking AHR activation to lung damages

Yuan Jin, Guangshuai Qi, Yingqing Shou et al. · Journal of Hazardous Materials · 2021 · 61 citations · Full text

Pharmacy, Molecular Biology, Toxicology +17

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Noel W. Clarke, Andrew J. Armstrong, Antoine Thiery-Vuillemin et al. · Journal of Clinical Oncology · 2023 · 53 citations

Medicine, Oncology, Pharmacology +16

Dynamic oxygen-enhanced magnetic resonance imaging of the lung in asthma—Initial experience

Weijuan Zhang, Robert Niven, Simon Young et al. · European Journal of Radiology · 2014 · 41 citations · Full text

Medicine, Radiology, Biomedical Imaging +16